Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Durata Therapeutics
Durata Therapeutics
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
Yahoo
Mon, 11/17/14 - 08:55 am
Actavis
Durata Therapeutics
M&A
Actavis buying Durata Therapeutics for $616.4
Yahoo/AP
Mon, 10/6/14 - 09:18 am
Actavis
Durata Therapeutics
M&A
Is Durata's Antibiotic Overpriced? A Twitter Conversation
Forbes
Thu, 08/7/14 - 02:33 pm
Durata Therapeutics
antibiotics
twitter
social media
Dalvance
The Medicines Company
oritavancin
Device maker, drug company plunge by double digits on weak earnings
Marketwatch
Thu, 08/7/14 - 02:18 pm
devices
earnings
Durata Therapeutics
Thoratec
Investing to Fight Toilet and Elevator Superbugs
Motley Fool
Sun, 07/20/14 - 09:19 am
Durata Therapeutics
Cubist Pharmaceuticals
Cubist and Durata Heat Up Antibiotic Market
Motley Fool
Tue, 06/24/14 - 09:51 am
Cubist Pharmaceuticals
Durata Therapeutics
antibiotics
Dalvance
Sivextro
ceftolozane/tazobactam
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
Yahoo/Globe Newswire
Sat, 05/24/14 - 09:44 am
Durata Therapeutics
Dalvance
MRSA
skin infection
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix
Seeking Alpha
Fri, 04/25/14 - 11:21 am
antibiotics
Cubist Pharma
Durata Therapeutics
Cellceutix
Pfizer Blockbuster Zyvox Under Attack
Motley Fool
Tue, 04/8/14 - 09:48 am
Pfizer
Zyvox
Durata Therapeutics
Cubist Pharmaceuticals
antibiotics
3 Biotechs With Major Catalysts Incoming
Motley Fool
Wed, 03/19/14 - 11:22 am
dalbavancin
Durata Therapeutics
MannKind
Afrezza
Cologuard
EXACT Sciences
Keep An Eye On GW, Johnson & Johnson, Durata, and Merck Today
Motley Fool
Wed, 11/27/13 - 09:58 am
JNJ
Durata Therapeutics
Merck
GW Pharma
Olysio
Savitex
Noxafil
Dalvance
2014 FDA Drug Approval Decision Calendar
TheStreet.com
Wed, 11/27/13 - 08:39 am
FDA
drug approvals
GSK
Gilead
Theravance
Auxilium
Amarin
Bristol-Myers Squibb
Biogen Idec
Pozen
Vanda
Chelsea Therapeutics
pSivida
Alimera
United Therapeutics
Biomarin
JNJ
Pharmacyclics
Celgene
MannKind
Santarus
AstraZeneca
Durata Therapeutics
Eli Lilly
Omeros
BioDelivery Sciences
Anacor
Keryx
Cubist Pharmaceuticals
Nektar
Durata Therapeutics presents new efficacy review of dalbavancin
The Fly on the Wall
Wed, 10/2/13 - 09:33 am
Durata Therapeutics
dalbavancin
skin infections
5 Low-Debt Biotech Stocks Forecasted For Growth
Seeking Alpha
Sat, 09/22/12 - 02:24 pm
Merrimack Pharmaceuticals
Durata Therapeutics
BioSpecifics Technologies
Pain Therapeutics
Acadia
Partnering Activity Skyrockets as Biotechs Close Year-End Deals
BNET Pharma
Wed, 12/23/09 - 08:42 am
biotech
* Incyte
Eli Lilly
OncoGenex
Teva Pharmaceuticals
Biovitrum
Eisai
AkaRx
Thallion Pharmaceuticals
LFB Biotechnologies
Athersys
Pfizer
Myriad
Javelin
Durata Therapeutics
Vicuron